Accessibility Menu
Inoviq Ltd logo

Inoviq Ltd(ASX) IIQ

Market CapA$26.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-73%
5 Year-73%
1 Year-54%
1 Month-16%
A$0.20
+2.63%
+0.01Today
Inoviq Ltd last closing stock price
MetricPriceDate
Last closeAUD 0.192026-08-13
Inoviq Ltd stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.56%AUD 0.202026-08-06
1 month-15.56%AUD 0.232026-07-14
3 month-40.63%AUD 0.322026-05-15
Year to date-50.9%AUD 0.392025-12-31
1 year-54.44%AUD 0.422025-08-13
3 year-73.97%AUD 0.732023-08-14
5 year-72.86%AUD 0.702020-12-04
Since inception-72.8%AUD 0.702016-06-20

Inoviq Ltd Financials at a Glance

Market Cap

A$26.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.41M

Net Income (TTM)

-A$14.32M

EPS (TTM)

-A$0.06

P/E Ratio

-3.09

Dividend

A$0.00

Beta (Volatility)

-0.02 (Low)

Price

A$0.20

Volume

11,407

Open

A$0.19

Previous Close

A$0.19

Daily Range

A$0.19 - A$0.20

52-Week Range

A$0.19 - A$0.57

Estimated Earnings Date

Sep 1, 2026

IIQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inoviq Ltd

INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, focusing on improving cancer detection and treatment. The company operates primarily in Australia and the United States, with a robust portfolio that includes innovative diagnostic tests.

Products and Services
  • hTERT test for bladder cancer screening
  • EXO-NET for exosome capture from liquid biopsies
  • Diagnostic pipeline for ovarian and breast cancer blood tests
Growth Outlook
  • Recent revenue growth of 229,584 AUD in Q2 2025
  • Strong cash position with 13.8 million AUD in cash and equivalents
  • Ongoing development of new diagnostic tests enhances market potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of 2.3 million AUD
  • Current ratio of 7.56 indicates strong liquidity
  • Net income loss of 3.96 million AUD in the latest quarter
INOVIQ Ltd is positioned in the healthcare sector, specifically within medical diagnostics and research. The company has made significant strides in developing innovative products aimed at enhancing cancer detection and treatment. The hTERT test and EXO-NET are key offerings that demonstrate the company's commitment to advancing diagnostic capabilities. The growth outlook appears promising, with recent revenue figures indicating a positive trend. The substantial cash reserves provide a solid foundation for ongoing research and development efforts, which are crucial for expanding the product pipeline. Financially, while the company reported a net income loss in the latest quarter, the current ratio suggests a strong ability to meet short-term obligations. The focus on developing new diagnostic tests is expected to drive future growth, making INOVIQ Ltd an intriguing option for investors interested in the healthcare and diagnostics sector.
AI Generated • Jul 27, 2026

Industry

Healthcare Providers and Services

CEO

Leearne Maree Hinch, PhD, MBA

Headquarters

Notting Hill, VIC 3168, AU

IIQ Financials

Key Financial Metrics (TTM)

Gross Margin

-47.93%

Operating Margin

-834.20%

Net Income Margin

-594.92%

Return on Equity

-37.14%

Return on Capital

-62.01%

Return on Assets

-29.52%

Earnings Yield

-32.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$26.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

140.78M

Volume

11.41K

Avg. Volume

364.73K

Financials (TTM)

Gross Profit

-A$2.77M

Operating Income

-A$21.34M

EBITDA

-A$14.47M

Operating Cash Flow

-A$9.63M

Capital Expenditure

-A$173.95K

Free Cash Flow

-A$9.80M

Cash & ST Invst.

A$13.80M

Total Debt

A$270.32K

Inoviq Ltd Performance Analysis

Inoviq Ltd annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 276,745N/A
20232023-06-30AUD 398,19343.9%
20242024-06-30AUD 535,11834.4%
20252025-06-30AUD 547,5752.3%
Inoviq Ltd sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30264.7%
Q22024-12-31-39.3%
Q42025-06-3019.1%
Q22025-12-31-76.7%
Inoviq Ltd annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.20N/A
20232023-06-30AUD -0.10-51.3%
20242024-06-30AUD -0.07-27.3%
20252025-06-30AUD -0.06-12.1%
Inoviq Ltd sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-8.5%
Q22024-12-3110.6%
Q42025-06-3010.9%
Q22025-12-31-9.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$229.58K

+127.7%

Gross Profit

A$190.91K

+5.3%

Gross Margin

83.16%

N/A

Market Cap

A$26.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.78M

N/A

Employees

15

N/A

Net Income

-A$3.96M

-26.6%

EBITDA

-A$5.01M

-84.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$13.80M

+131.0%

Total Debt

A$270.32K

-52.7%

Accounts Receivable

A$1.14M

+78.5%

Inventory

A$43.71K

+200.1%

Long Term Debt

A$155.75K

-36.2%

Short Term Debt

A$114.56K

-82.5%

Return on Assets

-29.52%

N/A

Return on Invested Capital

-45.14%

N/A

Free Cash Flow

-A$2.22M

-32.1%

Operating Cash Flow

-A$2.18M

-41.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMD.AXEmyria Limited
A$0.05+0.00%
RHY.AXRhythm Biosciences Limited
A$0.08-1.23%
LGP.AXLittle Green Pharma Ltd
A$0.08+1.33%
BDX.AXBCAL Diagnostics Limited
A$0.06+1.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About IIQ

What is the current price of Inoviq Ltd?

Inoviq Ltd is trading at A$0.20 per share.

What is the 52-week range for Inoviq Ltd?

Over the past 52 weeks, Inoviq Ltd has traded between A$0.19 and A$0.57.

How much debt does Inoviq Ltd have?

As of the most recent reporting period, Inoviq Ltd reported total debt of A$376.19K.

How much cash does Inoviq Ltd have on hand?

Inoviq Ltd reported A$6.52M in cash and cash equivalents in its most recent financial results.

What is Inoviq Ltd’s dividend yield?

Inoviq Ltd does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.